Immutep Quarterly Activities Report Q2 FY24Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing...
Globe Newswire•6 months ago